Your browser doesn't support javascript.
loading
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.
Gehin, Johanna Elin; Syversen, Silje Watterdal; Warren, David John; Goll, Guro Løvik; Sexton, Joseph; Bolstad, Nils; Hammer, Hilde Berner.
Afiliação
  • Gehin JE; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway johgeh@ous-hf.no.
  • Syversen SW; Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Warren DJ; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Goll GL; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
  • Sexton J; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Bolstad N; Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
  • Hammer HB; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
RMD Open ; 7(3)2021 12.
Article em En | MEDLINE | ID: mdl-34911811
OBJECTIVES: To identify the therapeutic range for etanercept and to assess the incidence of anti-etanercept antibody formation. METHODS: Associations between etanercept serum concentration and disease activity as well as treatment response were examined in a longitudinal observational study of rheumatoid arthritis patients starting etanercept. Disease activity was assessed by ultrasound (grey scale and power Doppler), 28-joint Disease Activity Score (DAS28), Simplified Disease Activity Index, plasma calprotectin and C reactive protein. Etanercept concentration and anti-etanercept antibodies were analysed using automated in-house fluorescence assays. RESULTS: A total of 89 patients were included, whereof 66% were biological disease-modifying antirheumatic drug (DMARD) naïve and 91% used concomitant synthetic DMARD. At 3 months, the median etanercept concentration was 1.8 (IQR 1.1-2.5) mg/L. Longitudinal associations were found between etanercept concentration and disease activity assessed by plasma calprotectin, C reactive protein and DAS28, but not between etanercept concentration and improvement in disease activity by any of the parameters at 3, 6 or 12 months of treatment. Etanercept concentrations were not significantly different among patients who achieved response or remission, compared with non-response or non-remission. Hence, no therapeutic range could be identified. None of the patients developed anti-etanercept antibodies. CONCLUSION: Despite the use of sensitive and objective markers of inflammation, a therapeutic range could not be identified for etanercept. Hence, this study suggests that proactive therapeutic drug monitoring is unlikely to benefit rheumatoid arthritis patients treated with etanercept, but a potential benefit in certain clinical situations cannot be excluded.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article